Table 2.

Reported treatment response rates of examined uricase-based therapies

	Pegloticase [8, 9, 22, 23]	Pegadricase [11, 25–27, 39]	Rasburicase [12, 30, 33, 34]
Underlying cause of hyperuricemia	Uncontrolled gout	Uncontrolled gout	Tumor lysis syndrome
FDA approval status	Approved with indication	Phase II (NCT03905512)	Approved with indication
Efficacy, n/N (%)
Monotherapy	36/85 (42%)	N/A	80/92 (87%)
With immunomodulation	68/82 (83%)a	115/143 (81%)	N/A
Patients with antidrug antibodies, n/N (%)
Monotherapy	134/150 (89%)	5/5 (100%)	17–18/28 (61–64%)b
With immunomodulation	2/14 (14%)	N/A	N/A

FDA US Food and Drug Administration, N/A not available

^aPooled response rate for immunomodulation with methotrexate, mycophenolate mofetil, leflunomide, azathioprine, and cyclosporin

^bRates of binding and neutralizing antibodies examined in healthy controls, respectively